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Introduction 
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Periodontitis is a disease that affects the tooth-supporting tissues and exhibits 
a wide range of clinical, microbiological, and immunological manifestations. It is 
associated with and probably caused by a multifaceted dynamic interaction among 
specific infectious agents, host immune responses, hazardous environmental 
exposure, and genetic propensity. Hormonal influences on the periodontium are 
many, with widely varying clinical presentations and degrees of effect. The primary 
hormonal factor is associated with diabetes mellitus.  
Diabetes mellitus (DM) causes inflammatory complications, including 
Retinopathy, Nephropathy, Neuropathy, Macro vascular disease, Altered wound 
healing, Periodontal disease 1. 
Diabetes mellitus is a chronic metabolic disorder caused by inherited or 
acquired deficiency in production of insulin by the pancreas or by the 
ineffectiveness of the insulin action. In diabetic patients, hyperglycemia could 
indirectly exacerbate inflammatory tissue destruction through the body's scavenger 
system against advanced glycation end-products and that hyperglycemia might 
directly impair the biological functions of periodontal connective tissues through 
cell–matrix interactions. It is suggested that an infection-mediated regulation cycle 
of cytokine synthesis and secretion by chronic stimulus from lipopolysaccharide and 
products of periodontopathogenic organisms may amplify the magnitude of the 
advanced glycation end-product mediated cytokine response operative in DM. Dual 
pathway of tissue destruction suggests that control of chronic periodontal infection 
and gingival inflammation is essential for achieving long-term control of DM1,2. 
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Calprotectin is a heterodimer of calcium-binding protein contained in the 
cystosol of neutrophils, monocytes/macrophages and epithelial cells. This protein 
belongs to the S100 protein family and forms approximately 5% of the total cellular 
protein and 50% to 60% of cystosol protein in granulocytes. The biological role of 
the S100 proteins are: regulation of the protein kinases, antimicrobial activity, and a 
regulatory role in inflammatory reactions3. 
Calprotectin exists normally in human plasma, saliva, and feces. Its level 
elevates remarkable in various infections and tissue damaging disorder. In recently, 
numerous studies have emerged documenting that increased levels of calprotectin 
are present in patients with diabetes, cardiovascular diseases and various cancers. 
Inflammed gingiva were found to contain vast numbers of calprotectin positive 
macrophages around the vessels in central connective tissue and adjacent to the 
epithelium. Calprotectin and its subunits have also been found in the gingival 
crevicular fluid from diseased gingival sites of periodontal patients, and the 
concentrations of calprotectin and its subunits were significantly higher in diseased 
sites than in healthy sites.  
The level of calprotectin in the gingival crevicular fluid of periodontitis 
patients was positively correlated with clinical parameters and biochemical markers, 
including probing depth, interleukin1β, prostaglandinE2, collagenase and aspartate 
aminotransferase. 
Calprotectin is released from leukocytes during inflammatory events in the 
initial steps of inflammation and its extracellular function including antibacterial, 
chemotactic for neutrophils and inhibition binding of pathogenic bacteria to 
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epithelial cells, suggest that calprotectin may play a role in the immune response 
mechanism of periodontal inflammation. 
The calprotectin exerts a regulatory activity in inflammatory processes 
through its effect on the survival or growth states of cells participating in the 
inflammatory reaction. It is also possible that calprotectin, at a high concentration, 
might have a deleterious effect on fibroblasts and influence the recovery of 
inflammatory tissue. Therefore, the protein factor may be a new drug target to 
control inflammatory reactions4. 
The main goals of non surgical periodontal therapy (scaling and root 
planning SRP) is to eliminate bacterial deposits and by removing the supragingival 
and subgingival biofilms and to restore the biological compatibility of periodontally 
diseased root surfaces for subsequent attachment of periodontal tissues to the treated 
root surface. The mechanical therapy alone may fail to eliminate pathogenic bacteria 
in the soft tissue and in areas that are inaccessible to periodontal instruments, such 
as deep pockets, furcation areas, and root depressions5. 
  To overcome these limitations of mechanical therapy, several adjunctive 
protocols have been developed. The use of lasers has been proposed for its 
bactericidal and detoxification effects and for its capacity to reach sites that 
mechanical instrumentation. 
The laser technology was introduced in dentistry in the 80’s, their 
performances as therapeutic methods constantly growing and being largely accepted. 
Recently, the low frequency laser has been introduced. This type of laser is 
characterized by a 400–900 nm low wavelength spectrum and biostimulation and 
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biomodulation properties, due to the capacity of this wavelength spectrum to modify 
tissue behavior, through its action on the calcium channels initiating an increase of 
the cellular metabolism and proliferation rate6. 
GCF calprotectin level decreases after the periodontal treatment7. The 
present study was done to investigate the effect of laser as an adjunct to non-surgical 
periodontal treatment in GCF calprotectin level of type II diabetic patients. 
Hence the aim of this study was designed to estimate the levels of 
Calprotectin level in GCF of subjects with chronic periodontitis with diabetic 
mellitus, after 1st and 4th weeks of scaling and root planning and also scaling and 
root planing with LASER in DM with chronic periodontitis subjects. 
 
Aim and Objectives  
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The aim of the present study is:  
1) To compare the effect of scaling root planing along with laser and scaling root 
planing alone in type II diabetic patients. 
2) Effect of laser therapy on GCF calprotectin level in type II diabetic patients. 
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Diabetes mellitus and periodontitis: 
Periodontal diseases are inflammatory in nature; they may alter glycemic 
control in a similar manner to obesity. Diabetic patients with periodontal infection 
have a greater risk of worsening glycemic control over time compared to diabetic 
subjects without periodontitis.3 Periodontal intervention trials suggest a significant 
potential metabolic benefit of periodontal therapy in people with diabetes. Several 
studies of diabetic subjects with periodontitis have shown improvements in glycemic 
control following scaling and root planning combined with adjunctive systemic 
doxycycline therapy.8 
Steven P E 20049, GCF samples were collected from 45 patients with Type 
II DM and untreated chronic periodontitis. IL-1β levels were determined. He 
concluded that poor glycemic control is associated with GCF IL-1β and also the 
hyperglycaemia contributes to a heightened inflammatory response between poor 
glycemic and periodontal destruction.  
Campus G et al 200510, studied on total of 212 individuals participated in 
that 71 Type II DM patients aged 61.0 ± 11.0 years and 141 non-diabetic controls in 
good general health aged 59.1 ± 9.2 years. All subjects were given a clinical 
periodontal examination for probing depth, attachment level, presence of calculus, 
bleeding on probing, and assessment of plaque. Subgingival plaque samples were 
obtained, and P. Gingivalis, P. Intermedia, and T. Forsythensis were identified using 
multiplex polymerase chain reaction. Concluded patients with Type II DM 
undoubtedly have susceptibility for more severe periodontal disease. 
Review of Literature 
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Katz J et al 200511, gingival biopsies from eight patients with both type II 
diabetes and chronic periodontitis and 14 healthy control subjects with chronic 
periodontitis were immune histochemically stained for RAGE. It’s giving a 
judgement that there was no change in the staining intensity for RAGE between both 
groups, the increase in the mRNA for RAGE in the type II diabetes gingival 
epithelium may indicate a possible involvement of this receptor in the periodontal 
destruction in type II diabetes.   
Calprotectin  
Calprotectin is an important proinflammatory mediator with multiple 
regulatory functions in periodontitis and diverse inflammatory diseases. It is 
therefore reasonable to consider the calprotectin gene as an ideal candidate for 
conferring genetic susceptibility to periodontitis. 
Miyasaki et al 199812 identified calprotectin in adult dental calculus and 
GCF. He indicated that calprotectin level in GCF from diseased pocket of patients 
with periodontitis is significantly higher than the healthy gingival cervices.  
Kido J et al 199913, in his study reviewed to investigate the correlations 
between GCF calprotectin levels and clinical indicators (probing depth and bleeding 
on probing, BOP), and the IL-1b or PGE2 levels in GCF. He derived that 
calprotectin level in GCF correlates well with clinical biochemical markers of 
periodontal disease and suggests that calprotectin may be useful for evaluating the 
extent of periodontal inflammation. 
Teuro N at al 200014, Association of GCF calprotectin level with GCF 
volume, GI, level of biochemical markers including collagenase and AST in GCF 
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was investigate to clarify the relationship between GCF calprotectin level and 
periodontal inflammation. It can be inferred that GCF calprotectin level significant 
correlates not only with clinical indicators but also with current biochemical marker 
level. 
Nisapakultorn K et al 200115, study was to assess the effect of epithelial 
calprotectin expression on an invasive periodontal pathogen P. gingivalis, and to 
provide evidence for the role of calprotectin in innate host defense in periodontal 
disease. He observed that epithelial calprotectin expression may have a protective 
role in periodontal diseases. Reduced P. gingivalis binding and invasion into 
epithelial cells could reduce bacterial colonization and persistence during the 
infections. And also increased calprotectin expression during periodontitis may 
reflect complimentary innate mucosal host defense mechanisms in response to P. 
gingivalis infection. 
Nisapakultorn K et al 200116 studied the antimicrobial protein complex 
epithelial resistance to invading bacteria; an epithelial cell line was stably 
transfected to express the calprotectin complex. Data provide supporting evidence 
that calprotectin expression in mucosal epithelial cells may play a protective role in 
innate host defense. Calprotectin expression reduces epithelial invasion by 
pathogens, including Listeria and Salmonella. Calprotectin mediates protection 
against invasion in vitro by several novel mechanisms. Associated with expression, 
bacterial binding is reduced. It remains unclear if the effect of calprotectin is 
associated directly or indirectly with cell surface calprotectin. Cell surface α3 
integrin is upregulated with calprotectin and is likely to reduce access to key 
receptors. Calprotectin also interferes with internalization, perhaps by modifying 
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calcium signaling and actin organization. These mechanisms may complement 
antimicrobial activity of calprotectin within the cytoplasm. Based on in vitro 
experiments, calprotectin is a multifunctional protein employing several modes of 
action to contribute to innate epithelial immunity against infection. 
Kido J et al 200317 studied on calprotectin which release by P-LPS was 
induced via the CD14–TLR–NF-jB pathway and the cellular mechanism of 
calprotectin release in human neutrophils. He concluded that calprotectin release is 
induced by P-LPS via the CD14, TLR2, NF-κB signal pathway in human 
neutrophils and may be dependent on microtubule and microfilament systems. 
Que M L et al 200418 Fifteen healthy non-smoking subjects, aged 18–30, 
were involved in this study GCF samples collected with Dura pore strips from 12 
sites in each subject. Quantitative analyses of total proteins, MRP8/14, MRP14 and 
MRP8 were performed by ELISA procedures. He observed that expression of 
calprotectin in the early phase of experimental gingivitis is variable between 
subjects, and two groups of subjects can be differentiated according to their response 
patterns. 
Suryono et al 200519 investigated the expression and production of 
calprotectin from human monocytes by examining the effect of lipopolysaccharide 
of P-LPS, TNF-α, and IL-1β by ELISA. Derived that P-LPS, TNF-α, and IL-1β 
treated monocytes from human monocytes that this producton is associated with 
activation of DNA C/EBPα binding complex. 
Kaner D et al 200720 was analysed the calprotectin in GCF as a predictive 
biomarker in periodontal therapy. 
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Sun X et al 20113, studied the plasma concentrations of calprotectin and 
were measured, using an enzyme immunoassay, in 139 patients with aggressive 
periodontitis and in 88 periodontally healthy control subjects. He observed that 
aggressive periodontitis is associated with elevated levels of plasma calprotectin and 
that gene polymorphisms of S100A8 may influence the susceptibility and severity of 
aggressive periodontitis.  
Kaner et al 201121 found elevated levels of calprotectin in gingival 
crevicular fluid and predicted disease activity in patients treated for generalized 
aggressive periodontitis. 
Sema B et al 201122 investigated gingival crevicular fluid (GCF) 
calprotectin, osteocalcin and cross-linked N-terminal telopeptide (NTx) levels in 
health along with different periodontal diseases. Results suggested that elevated 
GCF calprotectin levels play a role as a reliable inflammatory marker in the 
pathogenesis of periodontal disease. Fluctuating GCF levels of osteocalcin and NTx 
might point out to the abnormal bone turnover in periodontitis. Data document for 
the first time the role of NTx in the pathogenesis of different periodontal diseases. 
Biomarkers  
 Biomarkers may be defined as a substance that is measured objectively and 
evaluated as an indicator of normal biologic processes, pathogenic processes and 
pharmacologic responses to a therapeutic intervention. Biomarkers are produced by 
normal healthy individuals or by individuals affected by specific systemic diseases, 
are tell-tale molecules that could be used to monitor health status, disease onset, 
treatment response and outcome. 
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 Gingival crevicular fluid: 
Gingival crevicular fluid is inflammatory exudate that seeps into gingival 
crevices or periodontal pocket around teeth with inflamed gingival. The amount of 
GCF produced at a given site significantly increase with the severity of gingival 
inflammation23. 
Several techniques have been employed for the collection of GCF and the 
technique chosen will depend upon the objectives of the study as each technique has 
advantages and disadvantages. The techniques can be divided into three basic 
strategies, subject to various modifications in their application by different authors. 
1) Gingival washing methods 2) Capillary tubing or micropipettes 3) Absorbent 
filter paper strips24  
Leo 196125 was one of the fiest to speculate on the mechanism of gingival 
fluid production. The concentration of total protein in fluid from inflamed gingival 
is very similar to that of serum while in normal crevices it is lower. 
Pashely D H 197625 reviewed that in 1952; investigate the physiological 
properties of the gingival pocket, observed increased fluid transduction and 
emigration of leukocytes. Only through the efforts of Brill and co-workers, the 
phenomenon of gingival fluid production was discovered and early attempts were 
made to characterized the fluid,  
Curtis et al 198826 reviewed that gingival crevicular fluid is regarded as a 
promising medium for the detection of markers of periodontal disease activity, 
because the fluid accumulation at the gingival margin, it will contain potential 
markers derived not only from the host tissue and serum but also the subgingival 
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microbial plaque and thus an extremely broad range of candidate molecule may be 
investigated. 
Uitto V J 200327 reviewed that gingival crevicular fluid is a complex 
mixture of substance derived from serum, leukocytes, structural cells of the 
periodontium and oral bacteria. These are indicators of periodontal disease and 
healing after therapy. 
Champagne et al 200328 explores the inflammatory mediator levels in 
subjects with periodontal diseases. Their results suggest that some inflammatory 
mediator levels increase with time in periodontitis patients both in active and stable 
periodontal sites and that the risk for periodontitis is related to the overall systemic 
inflammatory response of an individual. 
 Catherine M E 200328 reviewed that lipopolysaccharide triggers monocytes 
to release inflammatory mediators (prostaglandin E2, thromboxane B, interleukins -1, 
-6 and -8, tumor necrosis factor, and collagenase) that increase local destruction of the 
connective tissues structural elements. Therefore, levels of monocytic inflammatory 
mediators (including prostaglandin E2, interleukin-1, and tumor necrosis factor) in 
GCF may well represent the ideal markers of disease activity at a site level. 
Armitage G C 200424 reviewed the possible biomarkers in gingival 
crevicular fluid for the progression of periodontitis. These components fall into 3 
general categories. 
1) Host derived enzyme and their inhibitors. 
2) Inflammatory mediators and host response modifiers. 
3) Tissue breakdown products. 
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Over 65 GCF components have been examined as possible markers for the 
progression of periodontitis. 
1) Host derived enzyme: 
Aspartate, aminotransferase, alkaline phosphatase, acid phosphatase, β-
glucuronidase, elastase, elastase inhibitors, cathepsins, trypsin like enzyme, 
immunoglobulin-degrading enzyme, glycosidases, dipeptidyl peptidases, nonspecific 
neutral proteinases, collegenases (MMP-1,3,8,13), gelatinases (MMP-2,9), TIMP-1, 
stomyelysins, myeloperoxidases, lactate, arylsulfatase, creatinine kinase. 
2) Inflammatory mediators and host response modifiers: 
 Cytokines, RANTES, prostaglandin E2, leukotriene B4, acute phase proteins, 
auto antibodies, antibacterial antibodies, plasminogen activator, PA inhibitor-2, 
substance P, vasoactive intestinal peptide, neurokinin A, neopterin, platelet- 
activating factors, CD14, cystatins, calgranulin A. 
3) Tissue breakdown products: 
 Glycosaminoglycans, hydroxyproline, fibronectin fragments, osteonectin, 
osteocalcin, type I collagen peptide, osteopontin, laminin, calprotectin, haemoglobin 
β-chain peptides, pyridinoline crosslinks (ICTP). 
LASER 
A laser is a device that produces coherent electromagnetic radiation. Laser 
radiation is characterized by a low divergence of the radiation beam and, with few 
exceptions, a well defined wavelength. The term laser is well known as the acronym 
for light amplification by stimulated emission of radiation. 
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Lasers are generally accepted and widely used as a tool for soft tissue 
management. The major advantageous properties of lasers are relative ease of 
ablation of tissues together with effective hemostasis and bacterial killing. 
Gingivectomy, gingivoplasty and frenectomy are the most popular procedures 
carried out using lasers.29 
Walsh L J 199730 Despite more than 30 years of experience with low level 
laser therapy (LLLT) or ‘biostimulation’ in dentistry, concerns remain as to its 
effectiveness as a treatment modality. Reported LLLT can influence the behaviour 
of many cell types, and that multiple effects can occur simultaneously. 
Eberhard J 200331, compared the effectiveness of subgingival calculus 
removal from periodontally involved root surfaces with an Er:YAG laser compared 
to hand instrumentation in situ . Concluded that in vivo capability of the Er:YAG 
laser to remove calculus from periodontally involved root surfaces, although the 
effectiveness did not reach that achieved by hand instrumentation. 
Qadri T et al 20056, studied in split-mouth, double-blind controlled clinical 
trial the effects of irradiation with low-level lasers as an adjunctive treatment of 
inflamed gingival tissue. They conclude that Additional treatment with low-level 
lasers reduced periodontal gingival inflammation. 
Charles M 200632 reported that clinical parameters of reductions in probing 
depth or gains in clinical attachment level, that indicates when used as an adjunct to 
SRP, mechanical, chemical, or laser curettage has little to no benefit beyond SRP 
alone. 
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Krause F 200733, To evaluate the removal of subgingival calculus and dental 
hard tissues depending on the threshold level of a fluorescence feedback controlled 
Er:YAG laser. Conclude that amount of residual calculus following laser irradiation 
depends on the fluorescence threshold level for a feedback-controlled Er:YAG laser. 
Isao I 200928 reviewed that animal study has reported that compared with 
conventional scalpel surgery, laser surgery produces less pain with the oral soft 
tissue incision. 
Zand et al.200934 investigated the use of CO2 laser (1W of defocused 
continuous mode) in 15 patients with recurrent aphthous ulcerations in comparison 
to the placebo (recurrent aphthous ulcerations which were not treated). Both 
ulcerations were covered with transparent gel without the use of anaesthetics. The 
power of CO2 laser was 2-5mW after passing through gel which did not 
significantly increase the temperature. The result was use of CO2 laser of low 
intensity instantly reduces pain in patients with recurrent aphthous ulcerations 
without any adverse effects 
Carlos D et al 201035 studied the effect of low-power lasers in the 
management of pathologies related to periodontal tissues. The clinical applications 
of laser phototherapy (LPT) include periodontal inflammation modulation, 
improvement in wound and bone healing processes, control of postoperative pain 
and post treatment tooth hypersensitivity, and microbial reduction when associated 
with an extrinsic photo sensitizer. 
Gokce A 201136 evaluate the effect of low-level laser therapy (LLLT) as an 
adjunct to non-surgical periodontal therapy of smoking and non-smoking patients 
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with moderate to advanced chronic periodontitis. And he concluded that LLLT as an 
adjunctive therapy to non-surgical periodontal treatment improves periodontal 
healing. 
Obradović R 201137 reported that Low level laser therapy was efficient in 
gingival inflammation elimination and can be proposed as an adjuvant tool in basic 
periodontal therapy of diabetic patients. 
The American Academy of Periodontology (AAP) 201138 Erbium lasers 
show the greatest potential for effective root debridement (SRP). There was the 
potential for root surface damage during the process of in vivo calculus removal 
since the Er:YAG is a hard tissue laser and the operator would not be able to 
visualize what is being lased. 
Radmila O 201239, to evaluate the effects of low-level laser therapy (LLLT) 
by exfoliative cytology in patients with DM and gingival inflammation. And he 
derived that LLLT as an adjunct in periodontal therapy reduces gingival 
inflammation in patients with DM and periodontitis. 
Catherine G 201240, studied was to compare the local biologic effects of 
PDT, diode soft laser (DSL) therapy, and conventional deep scaling and root planing 
(SRP) in residual pockets. And he concluded that, Levels of several cytokines and 
acute-phase proteins significantly changed after treatment regardless of treatment 
modality. There was no evidence for a specific DSL- or PDT-enhanced expression 
of inflammatory mediators. 
Obradović et al. 201241 treated patients with diabetes mellitus and 
periodontal disease by use of LLLT (670 nm, 5 mW, 2 J/cm², 16 minutes for five 
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days) together with conventional periodontal treatment. He observed that healing 
was improved as well as collagenization and homogenization in gingival lamina 
propria on the basis of histopathological findings. 
Fabrizio S 20125, To investigate whether the adjunctive use of diode laser 
provides additional benefits to scaling root planning alone in patients with chronic 
periodontitis, a meta analysis was conducted according to the recommendations of 
the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement 
and the Cochrane Collaboration and suggested that the use of diode laser as an 
adjunctive therapy to conventional nonsurgical periodontal therapy did not provide 
additional clinical benefit. 
Soo L et al 201242 To compare a monotherapy of Er:YAG laser debridement 
(ERL), wavelength 2940 nm, with mechanical scaling and root planing (SRP) for the 
treatment of chronic periodontitis using clinical and patient-centred outcomes. He 
observed that SRP resulted in a statistically significant greater short-term 
improvement in clinical parameters and patient satisfaction compared with ERL.  
Walter D 201343 evaluates the effect of a 980-nm diode laser as an adjunct 
to scaling and root planing (SRP) treatment. He concluded that comparison of SRP 
alone multiple adjunctive applications of a 980-nm diode laser with SRP showed PD 
improvements only in moderate periodontal pockets (4 to 6 mm). 
Jeffrey D 201344 found that Sites treated with the CO2 laser tended to show a 
greater decrease in probing depths, greater amounts of recession, and greater gains 
in clinical attachment levels, however the results were not statistically significantly 
better than scaling and root planing alone.   
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Mahnke et al. 199545.Determined that role of calprotectin in cellular 
adhesion has been reported as the monoclonal antibody 27E10 inhibiting the 
attachment of monocytes to collagen and fibronectin. On the other hand, these 
extracellular matrix proteins induced the expression of calprotectin in parallel with 
the release of inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and 
interleukin- 6 (IL-6) and production of superoxide anions. The relationship between 
calprotectin expressions and higher capacity to release TNF α has also been shown 
in human alveolar macrophages derived by bronchoalveolar lavage.   
Andersen E et al 201046 measured the levels of MRP8/14 longitudinally 
over 6 months in subjects with chronic periodontitis. And he confirmed clinical 
improvements after scaling and root planing. There was a significant decrease of 
MRP8/14 levels in diseased sites both at 3 and at 6 months after treatment. 
Anderson E study based on Giannopoulou C 200647 study showed a 
decrease of MRP8/14 after non-surgical periodontal therapy and significant changes 
were noted even after 10 days when non-surgical therapy was supplemented with 
systemic antibiotics. The improvements of biochemical parameters obtained in the 
present trial also compared favourably with previous reports on the effect of 
periodontal treatment on other gingival crevice fluid components. 
 
 
  
    Materials and Methods 
19 
 
A randomized controlled split mouth study was conducted to estimate the 
level of CALPROTECTIN in GCF of periodontal health, disease and after 
treatment. The protocol was reviewed and approved by institutional ethical board. 
An informed consent was obtained from the patients and the study related procedure 
was explained. A total of 60 subjects were recruited from the outpatient department 
of periodontics, J.K.K.N Dental College and Hospital, Komarapalayam, Tamilnadu 
based on the following criteria. 
Inclusion criteria: 
1) Age range 25- 65 years 
2) Should at least 20 natural teeth 
3) PD ≥4 
4) Diabetic patients with chronic periodontitis 
5) Systemic healthy subjects. 
Exclusion criteria: 
1) Treatment in the previous 6 months with anti-inflammatory drugs or antibiotics. 
2) Haematological disorder. 
3) Liver disorder. 
4) Patients with bone disorder. 
5) Pregnancy and lactating mother. 
6) History of recent bacterial or viral infection. 
7) Individual with habit of smoking and alcoholism. 
    Materials and Methods 
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STUDY DESIGN 
Criteria for subject grouping: 
 Based on plaque index, gingival index, probing pocket depth and clinical 
attachment level are categorized into 2 groups. 
Group I (healthy): consists of 30 subjects with clinically healthy periodontium. 
Group II (diabetic mellitus with chronic periodontitis): consists of 30 subjects with 
clinical signs of gingival inflammation. 
               Probing depth (PD) ≥4mm 
               Clinical attachment level (CAL) ≥ 2mm 
Group II A: Subgroup of Group II consists of 30 subjects under SRP. 
Group II B: Subgroup of Group II consists of 30 subjects under SRP + LASER. 
CLINICAL PARAMETERS 
 The following variables were measured at baseline and after 4 weeks of 
scaling root planing and scaling root planing along with LASER. 
1) Plaque index. 
2) Gingival index. 
3) Probing depth. 
4) Clinical attachment level. 
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1.  Plaque index (PI): (Silness P. and Loe H. in 1964) 
          0 – No plaque in the gingival area 
          1 – A film of the plaque adhering to the free gingival margin and adjacent area 
of the tooth. The plaque may be recognized only by running a probe across the tooth 
surface. 
          2 – Moderate accumulation of soft deposit within the gingival pocket or on the 
gingival margin and adjacent tooth surface. 
          3 – Abundance of soft matter within the gingival pocket or on the gingival 
margin and adjacent tooth surface. 
        The area examined were the distofacial, facial, mesiofacial and lingual surface 
using explorer. The plaque score was obtained by totalling by the four plaque scores 
per tooth and then divided by four. The plaque score per person is obtained by 
adding the plaque score per tooth and dividing by the number of teeth examined. 
2. Gingival index (GI): (Loe H. and Silness P.1963) 
                 The soft tissue surrounding each tooth were divided into 4 gingival 
scoring units i.e. the distofacial papilla, the facial margin, the mesiofacial papilla, 
and the entire lingual margin. A periodontal probing was used to assess the bleeding 
of the gingival tissue on probing. 
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Gingival units were assessed according to the following criteria: 
0 – Absence of inflammation/normal gingival 
1 – Mild inflammation, slight change in color, slight edema; no bleeding on probing. 
2 – Moderate inflammation; moderate glazing, redness, edema and hypertrophy, 
bleeding on probing. 
3 – Severe inflammation; marked redness, hypertrophy, ulceration and tendency to 
spontaneous bleeding. 
 The scores of the four areas of the tooth can be summed and divided by four 
to give the GI for the tooth. A score from 
0.1 – 1.0 – Mild inflammation 
1.1 – 2.0 – Moderate inflammation 
3.1 – 3.0 – Severe inflammations 
3. Probing depth (PD): 
 The depth was measured at selected sites with William’s periodontal probe. 
The probe was inserted parallel to the long axis of the tooth surface until resistance 
was felt and the readings were recorded to the nearest millimetre marking from the 
gingival margin to the base of the pocket. 
4. Clinical attachment level (CAL): 
            The level of attachment is the distance between the base of the pocket and 
cementoenamel junction (CEJ). The distance from the CEJ to the base of the pocket 
was measured. The readings were recorded to the nearest millimetre. 
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Clinical evaluation of subjects: 
             Subjects were selected for each group after a brief and precise case history 
recording that included patient’s chief complaint and clinical examination. Clinical 
examination was done using sterile mouth mirror and William’s periodontal probe. 
Site specific scoring was followed, where in the site showing most severe 
inflammation signs or greater amount of attachment loss was selected for GCF 
samples collection. PI and GI scores were recorded before to aid in site selection.  
PD and CAL measurement were recorded after GCF collection to avoid 
contamination of the sample. The split-mouth clinical study was performed by toss 
the coin. SRP was performed using a sonic device and hand instruments. DIODE 
LASER with a wave length of 810nm, 3mW in contact with gingival was used. 
Quadrants were equally divided between the right and left side. Teeth were treated 
with SRP on one side and the diode laser with SRP was used on the contra lateral 
side. Treatment was performed only during the initial stage of chronic periodontitis. 
Plaque index, Gingival index, Probing depth and Clinical attachment level was 
recorded at base line and at 4th week after periodontal treatment.  
Procedure for gingival crevicular fluid collection: 
            Subject selected for sampling were made to sit comfortably in an upright 
position on the dental chair with proper illumination. The test site selected for 
sampling was air dried; isolation with cotton roll and supragingival plaque was 
removed without touching marginal gingiva. Sample of GCF were obtained by 
placing white color   code 1 – 10µL calibrated volumetric micro capillary pipettes 
which were obtained from Sigma Aldrich chemical company Limited, USA. From 
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each test sites, a standardized volume of 3µL was collected using the calibration on 
the micropipette and placing the tip of the pipette extra crevicularly (unstimulated) 
for 5 to 20 minutes. GCF contamination with saliva and blood were discarded. 
 Samples of GCF were collected at initial visit in Group I, Group II, Group 
III, Group IV, Group V, Group VI subjects. Periodontal treatment (SRP and SRP + 
LASER) was performed for diabetic with periodontitis patients at the same 
appointment after GCF collection. After 1st and 4th week GCF was collected in 
periodontally treated sites. The GCF collected was immediately transferred to plastic 
vial and stored at -70°C till the time assay. 
 The samples were then assay for CALPROTECTIN levels by using Enzyme-
Linked Immunosorbent Assay kit. 
METHOD OF ESTIMATION OF CALPROTECTIN:  
 The kit is a sandwich enzyme immunoassay for in vitro quantitative 
measurement of calprotectin in human serum, plasma, tissue homogenates, cell 
lysates and other biological fluids. The microtiter plate provided in this kit has been 
precoated with a calprotectin. Standards or samples are then added to the appropriate 
microtiter plate wells with a biotin-conjugated antibody specific to calprotectin. 
Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each 
microplate well and incubated. After TMB substrate solution is added, only those 
wells that contain calprotectin and enzyme conjugated avidin will exhibit a change 
in color. The enzyme substrate reaction is terminated by the addition of sulphuric 
acid solution and the colour change is measured spectrophotometrically at a 
    Materials and Methods 
25 
 
wavelength of 450nm±10nm. The concentration of calprotectin in the samples is 
then determined by comparing the O.D. of the samples to the standard curve. 
ASSAY PROCEDURE:  
1) Determine wells for diluted standard, blank and sample. Prepare 7 wells for 
standard, 1 well for blank. Add 100µL each of dilutions of standard (read 
Reagent Preparation), blank and samples into the appropriate wells. Cover with 
the Plate sealer. Incubate for 2 hours at 37ºC.  
2)  Remove the liquid of each well, don’t wash.  
3)  Add 100µL of Detection Reagent A working solution to each well. Incubate for 
1 hour at 37ºC after covering it with the Plate sealer.  
4) Aspirate the solution and wash with 350µL of 1× Wash Solution to each well 
using a squirt bottle, multi-channel pipette, manifold dispenser or auto washer, 
and let it sit for 1~2 minutes. Remove the remaining liquid from all wells 
completely by snapping the plate onto absorbent paper. Totally wash 3 times. 
After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against absorbent paper.  
5)  Add 100µL of Detection Reagent B working solution to each well. Incubate for 
30 minutes at 37ºC after covering it with the Plate sealer.  
6) Repeat the aspiration/wash process for total 5 times as conducted in step 4.  
7) Add 90µL of Substrate Solution to each well. Cover with a new Plate sealer. 
Incubate for 15- 25 minutes at 37ºC (Don't exceed 30 minutes). Protect from 
light. The liquid will turn blue by the addition of Substrate Solution.  
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8)  Add 50µL of Stop Solution to each well. The liquid will turn yellow by the 
addition of Stop solution. Mix the liquid by tapping the side of the plate. If color 
change does not appear uniform, gently tap the plate to ensure thorough mixing.  
9)  Remove any drop of water and fingerprint on the bottom of the plate and 
confirm there is no bubble on the surface of the liquid. Then, run the microplate 
reader and conduct measurement at 450nm immediately.  
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APPENDIX-1 
PROFORMA 
Op no:  Date: 
Name:  Age/Sex: 
Occupation:  Address: 
 
Chief complaint: 
 
 
History of present illness: 
 
 
Present medical history: 
 
 
Past dental history: 
 
 
Family history: 
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Pre operative clinical examination: 
Plaque index: (Sillness P and Loe H 1964)  
16 12 24 
   
   
44 32 36 
 
Score: 
Interpretation:  
Gingival index (Loe H & Sillness 1963) 
16 12 24 
   
   
44 32 36 
 
Score: 
Interpretation:  
Scaling and root planing    Scaling and root planing +  
(Group II A)      LASER (Group II B) 
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Group Group II 
A 
Group II 
B 
Periodontal pocket depth   
Clinical attachment level   
 
Investigation: 
HB%:      HBA1c: 
Fasting glucose level: 
Postprandial glucose level: 
Diagnosis: 
Post operative clinical examination: 
Plaque index: (Sillness P and Loe H 1964)  
16 12 24 
   
   
44 32 36 
 
Score: 
Interpretation:  
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Gingival index (Loe H & sillness 1963 ) 
16 12 24 
   
   
44 32 36 
 
Score: 
Interpretation:  
Scaling and root planing    Scaling and root planing +  
(Group II A)      LASER (Group II B) 
 
 
 
 
 
 
 
 
Group  Group II A   Group II B 
Periodontal pocket depth   
Clinical attachment level   
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Consent form: 
Department of Periodontics, JKK Nataraja Dental College,    
Komarapalayam - 638183 
Patient name 
 I have been explained about the nature and purpose of the study in which, I 
have been asked to participate. I understand that I am free to withdraw my consent 
and discontinue at any time without prejudice to me or effect on my treatment. 
 I have been given the opportunity to question about the material and study. I 
have also given the consent for photographs to be taken at the beginning, during and 
at the end of the study. I have fully agreed to participate in this study. 
 I hereby given the consent to be included in “EFFECT OF LASER 
THERAPY ON GCF CALPROTECTIN LEVEL IN TYPE II DIABETIC 
PATIENTS – A CLINICAL AND BIOCHEMICAL STUDY” 
 
 
Station: Signature of the Patient 
Date: 
 Signature of Professor/ HOD   
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APPENDIX - 2 
ARMAMENTARIUM 
1. Gloves  
2. Mouth mask  
3. Patient apron  
4. Chair apron  
5. Head cap  
6. Sterile cotton rolls  
7. Gauze  
8. Kidney tray  
9. Mouth mirror  
10. Explorer  
11. William’s periodontal probe  
12. Tweezer  
13. Ultrasonic scalers  
14. Hu-Friedysupragingivalscalers  
15. Hu-FriedyGracey Curettes  
16. Microcapillary pipettes  
17. Eppendorf tubes  
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Fig 1: Armamentarium used for GCF collection and treatment 
 
Fig 2: Microcapillary pipettes and Eppendorfhoff tubes used for GCF collection 
  
    Photographs 
34 
 
CLINICAL CASES 
 
Fig 3: LASER Unit 
 
 
  
Fig 4: Probing depth measurement of pre operative view 
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                    Fig 5: GCF collection             Fig 6: LASER Sulcular Debridement 
 
 
 
 
Fig 7: probing depth measurement of post operative view 
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LAB ANALYSIS 
 
Fig 8: Calprotectin ELISA kit 
 
   
 Fig 9: ELISA PHOTOMETER Fig 10: ELISA ASSAY 
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Results of ELISA 
 
Fig 11: GCF samples in pipette 
 
 
Fig 12: Color changes in ELISA KIT 
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The present study was conducted to estimate the effect of laser therapy on 
GCF calprotectin level in type II diabetic patients. Also to comparison was made 
between the scaling root planing along with LASER to scaling root planing alone. 
The randomized clinical study consist of 60 subjects divided into 2 groups i.e., 
healthy (Group I – 30 subjects), diabetic with chronic periodontitis (Group II – 30 
subjects), aged between 25-65years from whom GCF was to collected to estimate the 
calprotectin level in GCF using ELISA.  
The result obtained were analysed statistically and comparisons were made 
each group using paired student t – distribution test. 
Comparison of clinical parameters:  
The plaque index (PI) scores in Group II were (1.22±0.26) pre operatively and 
reduced in Group II (0.96±0.19) post operatively. Comparison of plaque scores                   
pre operatively and post operatively in Group II was found to be statistically 
significant (P – value <0.05). The results are shown in table 1 and graph 1. 
The gingival index (GI) scores in Group II were (1.53±0.43) pre operatively 
and reduced in Group II (1.03±0.17) post operatively. Comparison of the GI scores 
pre operatively and post operatively in Group II was found to be statistically 
significant (P – value <0.05). The results are shown in table 1 and graph 1. 
The probing depth (PD) scores in Group II A were (4.93±0.89) pre operatively 
and reduced in Group II A (3.46±0.69) post operatively. Comparison of the PD scores 
pre operatively and post operatively in Group II A was found to be statistically 
significant (P – value 0.05). The results are shown in table 2 and graph 2. 
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The probing depth (PD) scores in Group II B were (5.40±1.04) pre operatively 
and reduced in Group II B (3.23±0.96) post operatively. Comparison of the PD scores 
pre operatively and post operatively in Group II B was found to be statistically 
significant (P – value <0.05). The results are shown in table 3 and graph 3. 
The probing depth (PD) scores post operatively in Group II A and Group II B 
were (3.46±0.69) and (3.23±0.96) respectively. Comparison of post operative PD 
scores between Group II A and Group II B showed no statistically significant 
difference (P – value >0.05). The results are shown in table 4 and graph 4. 
The clinical attachment level (CAL) scores in Group II A were (5.03±0.93) pre 
operatively and reduced in Group II A (3.53±0.76) post operatively. Comparison of the 
CAL scores pre operatively and post operatively in Group II A was found to be 
statistically significant (P – value <0.05). The results are shown in table 2 and graph 2. 
 The clinical attachment level (CAL) scores in Group II B were (5.56±1.22) pre 
operative and reduced in Group II B (3.33±1.09) post operative. Comparison of the 
CAL scores pre operatively and post operatively in Group II B was found to be 
statistically significant (P – value <0.05). The results are shown in table 3 and graph 3. 
The clinical attachment level (CAL) scores post operatively in Group II A and 
Group II B were (3.53±0.76) and (3.33±1.09) respectively. Comparison of post 
operative CAL scores between Group II A and Group II B showed no statistically 
significant difference (P – value >0.05). The results are shown in table 4 and graph 4. 
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Comparison of biochemical parameters: 
The GCF Calprotectin level in Group II A was (4.60±1.63) pre operatively 
and reduced to (2.21±0.39) 4th week post operatively in Group II A. Comparison of 
GCF Calprotectin level preoperatively and 4th week post operatively in Group II A 
showed statistically significant difference (P – value of <0.05). The results are 
shown in table 6 and graph 6. 
 The GCF Calprotectin level in Group II B was (4.60±1.63) pre operatively 
and reduced to (1.81±0.24) 4th week post operatively in Group II B. Comparison of 
GCF Calprotectin level preoperatively and 4th week post operatively in Group II B 
showed statistically significant difference (P–value of <0.05). The results are shown 
in table 6 and graph 6. 
The GCF Calprotectin level 4th week post operatively was significantly 
reduced in Group II B (1.81±0.24) compared to Group II A (2.21±0.39). 
Comparison of GCF Calprotectin level 4th week post operatively between Group II 
A and Group II B showed statistically significant difference (P – value <0.05). The 
results are shown in table 7 and graph 7. 
In summary, the results suggest that there is a statistically significant 
difference between SRP and SRP + LASER Groups preoperatively and post 
operatively in relation to Plaque index, Gingival index, Probing depth, Clinical 
attachment level scores. The Calprotectin level was significantly reduced post 
operatively in both SRP and SRP + LASER groups. There is statistically significant 
difference among SRP and SRP + LASER groups in Calprotectin level.    
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Table 1 
Comparison of clinical parameters in Group II subjects 
Clinical parameters of Group II Base line At 4th week P - value 
Plaque index 1.22±0.26 0.96±0.19 <0.05 
Gingival index 1.53±0.43 1.03±0.17 <0.05 
 
In Group II the P- Value between base line and 4th week post operative is 
<0.05 (denotes statistically significant). 
Table 2 
Comparison of clinical parameters in Group II A subjects 
 
In Group II A the P- Value between base line and 4th week post operative is 
<0.05 (denotes statistically significant). 
  
Clinical parameters of Group II A Base line At 4th week P - value 
Probing depth 4.93±0.89 3.46±0.69 <0.05 
Clinical attachment level 5.03±0.93 3.53±0.76 <0.05 
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Table 3 
Comparison of clinical parameters in Group II B subjects  
Clinical parameters of Group II B Base line At 4th week P value 
Probing depth 5.40±1.04 3.23±0.96 <0.05 
Clinical attachment level 5.56±1.22 3.33±1.09 <0.05 
 
In Group II B the P- Value between base line and 4th week post operative is 
<0.05 (denotes statistically significant). 
Table 4 
Comparison of clinical parameters in group II A and B at 4th week post 
operative 
Clinical parameter Group II A Group II B P Value 
Probing depth 3.46±0.69 3.23±0.96 >0.05 
Clinical attachment level 3.53±0.76 3.33±1.09 >0.05 
 
P-Value between Group IIA and Group II B at 4th week post operative is 
>0.05 (denotes statistically no significant). 
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Table 5 
Calprotectin levels: 
Groups Base line At 1st week At 4th week 
II A 4.60±1.63 2.56±0.48 2.21±0.39 
II B 4.60±1.63 2.10±0.32 1.81±0.24 
 
Table 6 
Inter Group comparison of Calprotectin levels: 
Groups Base line At 4th week P value 
II A 4.60±1.63 2.21±0.39 <0.05 
II B 4.60±1.63 1.81±0.24 <0.05 
 
Inter Group P-Value between Group IIA and Group II B in base line and at 
4th week post operative is <0.05 (denotes statistically significant). 
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Table 7 
Intra Group comparison of Calprotectin levels: 
Periods II A II B P Value 
At 1st week 2.56±0.48 2.10±0.32 <0.05 
At 4th weeks 2.21±0.39 1.81±0.24 <0.05 
 
Intra Group P-Value between Group IIA and Group II B in base line and at 
4th week post operative is <0.05 (denotes statistically significant). 
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Graph 1 
Comparison of clinical parameters in Group II subjects 
 
 
Graph 2 
Comparison of clinical parameters in Group II A subjects 
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Graph 3 
Comparison of clinical parameters in Group II B subjects 
 
 
Graph 4 
Comparison of clinical parameters in group II A and B at 4th week post 
operative 
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Graph 5 
Calprotectin levels: 
 
 
Graph 6 
Inter Groups comparison of calprotectin levels: 
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Graph 7 
Intra Groups comparison of calprotectin levels: 
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Periodontal diseases are a complex group of diseases characterized by 
inflammation and the subsequent destruction of the tooth supporting tissue. The 
destruction of the periodontal tissue is by bacterial infection and host immune 
response, either directly or indirectly by various mediators that can activate 
osteoclastic activity. As GCF permeates through the diseased soft tissue of the 
periodontal pocket, it contains molecules from the periodontal disease process and it 
is considered the most promising source of biochemical indicators like 
calprotectin.13 
According to Striz et al 200445, Calprotectin complex also known as L1 
antigen, calgranulin A and B, macrophage migration inhibitory factor-related protein 
8 and 14 (MRP8 and MRP14), S100A8/S100A9, and cystic fibrosis antigen, has 
several functions in inflammatory reactions. It acts as a chemotactic factor and 
regulates adhesion and migration of neutrophils or monocytes and is therefore 
considered as a pro-inflammatory marker. 
According to Kido J 199913 Higher levels of MRP 8 were detected in sites 
with periodontitis and gingivitis than in healthy sites. 
Our study comprised of  2 groups (healthy, diabetic with chronic 
periodontitis) compared to that of Yukari K et al 20147 which included patients 
with DM, chronic periodontitis, DM-P, and healthy individuals, but having no 
provision to evaluate the effect of LASER on calprotectin levels in GCF which can 
confirm the role of calprotectin in periodontal disease.  
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In our study, plaque index and gingival index were examined pre operatively 
and 4th week post operatively for all patients. The pre operative value of plaque 
index and gingival index [(1.22±0.26) and (1.53±0.43) respectively] was 
significantly reduced to [(0.96±0.19) and (1.03±0.17) respectively] postoperatively. 
Probing depth and Clinical attachment level were measured in Group II A 
pre operatively and 4th week post operatively. The 4th week post operative valve of 
Probing depth and Clinical attachment level [(3.46±0.69) and (3.53±0.76) 
respectively] was significantly reduced compared to pre operative valves 
[(4.93±0.89) and (5.03±0.93) respectively] in Group II A. 
Probing depth and Clinical attachment level was measured pre operatively 
and 4th week post operatively in Group II B. The 4th week post operative valve of 
Probing depth and Clinical attachment level [(3.23±0.96) and (3.33±1.09) 
respectively] was significantly reduced compared to pre operative valves 
[(5.40±1.04) and (5.56±1.22) respectively] in Group II B. 
Among the groups, the probing depth and clinical attachment level values for 
Group II B 4th week post operatively was significantly better. Dana V et al48 
demonstrated that the application of low level laser therapy (LLLT), in addition to 
standard procedures employed to treat periodontal disease, improved the outcome of 
the treatment. And also had improved healing times, less pain, less bleeding, less 
post surgery complications such as edema, inflammation, and infection compared 
with the classic treatment only group. 
Rozana D200549, demonstrated that local and general circulation of blood is 
reinforced on laser. Therefore the wound healing is better and inflammation is 
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reduced in Group II B 4th week post operative compared to Group II A 4th week post 
operative group. 
In our study, the mean concentration of Calprotectin in DM-P were reduced 
from 4.60±1.63 µg/ml (Group II A) to 2.56±0.48 (Group II A 1st week post 
operative), and 2.21±0.39 (Group II A 4th week post operative). 
The value of Calprotectin in Group II B 4.60±1.63 µg/ml were reduced to 
2.10±0.34 (Group II B 1st week post operative), and 1.81±0.24 (Group II B 4th week 
post operative). 
The study by Yukari K et al 20147 reported that the total amount of 
calprotectin in GCF samples from periodontitis cases were significantly higher than 
that from cases without periodontitis, but the calprotectin concentration in 
periodontitis samples was slightly lower. This difference between calprotectin 
amount and concentration was caused by the increase of GCF volume in 
periodontitis. The calprotectin amount and concentration were not affected by DM, 
and there was no significant correlation between GCF calprotectin level and HbA1c 
value. 
Suryono et al 200350 showed that MRP8/MRP14 existed in the epithelium 
and connective tissue of a periodontitis patient’s gingival using the monoclonal 
antibody 27E10, a macrophage marker that recognizes MRP8/MRP14 and suggested 
that macrophage in the connective tissue and epithelium cells expressed these 
proteins. 
 
 
    Discussion 
52 
 
Kido J 199913 demonstrated that the calprotectin level in GCF is positively 
related to clinical indicators (probing depth and BOP) and levels of known 
biochemical markers (IL-1b and PGE2) of periodontal disease, and it reflects the 
degree of gingival inflammation in patients with periodontal disease. Although 
Armitage 199610 showed that probing depth does not provide an accurate indication 
of the current severity of periodontal inflammation, eventhough it has been widely 
used to evaluate periodontal disease. 
The main findings in our study was that the mean concentration of 
calprotectin in GCF increased progressively from healthy to periodontitis which was 
in accordance with that of study done by Kido J et al13 who reported increasing 
calprotectin levels in GCF with progression of periodontal disease. 
The correlation of Calprotectin concentration with four clinical parameters of 
periodontal status was investigated. The Calprotectin level was positively correlated 
with PI and GI. This indicated that the Calprotectin levels were associated with the 
degree of periodontal tissue inflammation. 
Moreover the Calprotectin concentration was positively correlated with the 
PD and CAL. This indicated that the Calprotectin levels were positively correlated 
with the degree of periodontal tissue destruction. 
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Some of the conclusions that can be drawn from this study are: 
1) Calprotectin is detected in gingival crevicular fluid and its concentration is 
found to be higher in patients with chronic periodontitis with diabetic 
mellitus. 
2) Treatment of periodontal diseases by scaling and root planing led to a 
significant reduction in Calprotectin levels in GCF. There was a statistically 
significant reduction more in LASER plus scaling and root planing Group 
when compared to SRP alone. 
3) Further, as the concentration of Calprotectin correlated positively with the 
clinical parameters, it can be postulated that Calprotectin is actively involved 
in the progression of periodontal disease and thus could be a marker of 
periodontal destruction. 
To conclude, as per our study, it can be postulated that greater the 
periodontal destruction, there is substantial increase in Calprotectin concentration in 
GCF.  
 
 
    Bibliography 
54 
 
1) Brian I. Mealey & Gloria I. Diabetes mellitus and Periodontal disease. 
Periodontology 2000, Vol. 44, 2007, 127–153. 
2) Hamdy Nassar, Alpdogan Kantarci & Thomas E. Van Dyke. Diabetic 
periodontitis: a model for activated innate immunity and impaired resolution of 
Inflammation. Periodontology 2000, Vol. 43, 2007, 233–244. 
3) Sun X, Meng H, Shi D, Xu L, Zhang L, Chen Z, Feng X, Lu R. Analysis of 
plasma calprotectin and polymorphisms of S100A8 in patients with aggressive 
Periodontitis. J Periodont Res 2011; 46: 354–360. 
4)  Satoru Yui, Yuichi Nakatani, and Masaaki Mikami. Calprotectin 
(S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a 
Broad Apoptosis-Inducing Activity. Pharmaceutical Society of Japan March 
2003, Vol. 26, No. 6, 754. 
5) Fabrizio Sgolastra & Marco Severino & Roberto Gatto & Annalisa 
Monaco. Effectiveness of diode laser as adjunctive therapy to scaling root 
planning in the treatment of chronic periodontitis:a meta-analysis. Lasers Med 
Sci; 30 July 2012. 
6) Qadri T, Miranda L, Tuner J, Gustafsson A. The short-term effects of low-
level lasers as adjunct therapy in the treatment of periodontal Inflammation.     
J Clin Periodontol 2005; 32: 714–719. 
  
    Bibliography 
55 
 
7) Yukari Kajiura, Mika Bando, Yuji Inagaki, Toshihiko Nagata, and          
Junichi Kido. Glycated Albumin and Calprotectin Levels in Gingival 
Crevicular Fluid from Patients with Periodontitis and Type 2 Diabetes.                    
J Periodontol 2014; 85:1667-1675. 
8) George W. Taylor, Brian A. Burt, Mark P. Becker, Robert J. Genco, 
Marc Shlossman, William C. Knowler, and David J. Pettitt. Severe 
Periodontitis and Risk for Poor Glycemic Control in Patients with Non-
Insulin-Dependent Diabetes Mellitus. Journal of Periodontology; 96; 67;1085-
1093. 
9) Steven P. Engebretson, Judith Hey-Hadavi, Fernando J. Ehrhardt, Dan 
Hsu. Gingival crevicular fluid level of interleukin-1β and Glycemic control in 
patients with chronic periodontitis and type II diabetes. Journal of 
periodontology; 2004, 75, 1203-1208.  
10) Guglielmo Campus, Abeer Salem, Sergio Uzzau, Edoardo Baldoni, and 
Giancarlo Tonolo. Diabetes and Periodontal Disease: A Case-Control Study. 
J Periodontol 2005; 76: 418-425. 
11)  Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, 
Heft MW. Expression of the receptor of advanced glycation end products in 
gingival tissues of type II diabetes patients with chronic periodontal disease: a 
study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 2005; 
32: 40–44. 
    Bibliography 
56 
 
12) Kenneth T. Miyasaki, Alexandra Voganatsi, Thuc Huynh, Marvin 
Marcus, and Steven Underwood. Calprotectin and Lactoferrin Levels in the 
Gingival Crevicular Fluid of Children. Journal of Periodontology; 1998; 
69:879-883. 
13) Kido Jun-ichi, Nakamura T, Kido R, Ohishi K, Yamauchi N, Kataoka M, 
Nagata T. Calprotectin in gingival crevicular fluid correlates with clinical and 
biochemical markers of periodontal disease. J Clin Periodontol 1999; 26:    
653–657. 
14) Teruo Nakamura, Jun-ichi-Kido, Reiko Kido, Keijo Ohishi, Noriyoki 
Yamachi, Masatoshi Kataoka. The association of calprotectin level in 
Gingival crevicular fluid with Gingival index and the activities of collagenase 
and aspartate aminotransferase in adult periodontitis patients. Journal of 
Periodontol: 2000; 71;361-367. 
15)  Nisapakultorn K. Ross K.F and  Herzberg M. C. Calprotectin Expression 
In Vitro by Oral Epithelial Cells Confers Resistance to Infection by 
Porphyromonas gingivalis. Infect Immun. 2001 Jul; 69(7):4242-7. 
16)  Kanokwan Nisapakultorn, Karen F. Ross, and Mark C. Herzberg. 
Calprotectin Expression Inhibits Bacterial Binding to Mucosal Epithelial Cells.  
Infect Immun. 2001 Jun; 69(6): 3692–3696.  
  
    Bibliography 
57 
 
17) Kido J, Kido R, Suryono, Kataoka M, Fagerhol MK, Nagata T. 
Calprotectin release from human neutrophils is induced by Porphyromonas 
gingivalis lipopolysaccharide via the CD-14–Toll-like receptor–nuclear factor 
κB Pathway. J Periodont Res 2003; 38; 557–563. 
18)  Que ML, Andersen E, Mombelli A. Myeloid-related protein (MRP) 8/14 
(calprotectin) and its subunits MRP8 and MRP14 in Plaque - induced early 
gingival inflammation. J Clin Periodontol 2004; 31: 978–984. 
19) Suryono, Jun-Ichi Kido, Noriko Hayashi, Masatoshi Kataoka. Calprotectin 
in human monocytes: induction by Porphymonas gingivalis 
lipopolysaccharide, Tumor necrosis factor-α and Interleukin-1β. J Periodontol 
2005; 76; 437-442. 
20) Kaner D. W. Hopfenmüller, J.P. Bernimoulin, B.M. Kleber, and A. 
Friedmann. Calprotectin in GCF as a predictive biomarker in periodontal 
therapy. Periodontal Research: Diagnosis–Neuroscience September 28, 2007. 
21) Kaner D; Bernimoulin JP; Dietrich T; Kleber BM; Friedmann A. 
Calprotectin levels in gingival crevicular fluid predict disease activity in 
patients treated for generalized aggressive periodontitis. J Periodontal Res. 
2011 Aug; 46 (4):417-26. 
22) Sema Becerika, Beral Afacana, Veli O zgen O zturka, Harika Atmacab 
and Gulnur Emingila. Gingival crevicular fluid calprotectin, osteocalcin and 
cross-linked N-terminal telopeptid levels in health and different periodontal 
diseases. Disease Markers 31 (2011) 343–352. 
    Bibliography 
58 
 
23) Gareths, Griffiths. Formation, collection and significance of gingival crevice 
Fluid. Periodontology 2000, Vol. 31, 2003, 32–42. 
24) Gary C, Armitage. Analysis of gingival crevice fluid and risk of progression 
of periodontitis. Periodontology 2000, vol.34, 2004, 109-119.  
25) Pashley DH. A mechanistic analysis of gingival fluid production. J Periodont 
Res 1976; 11: 121-134.  
26) Curtis MA, Griffiths GS, Price SJ, Coulthurst SK, Johnson NW. The total 
protein concentration of gingival crevicular fluid. Variation with sampling 
time and gingival inflammation. J Clin Periodontol 1988; 15: 628-32.  
27) Veli- Jukka Vitto. Gingival crevice fluid – an introduction. Periodontology 
2000,Vol. 31, 2003, 9–11. 
28) Catherine. M.E Champagne, William. Buchanan, Michael S. Reddy, John 
S- Preisser. Potential for gingival crevice fluid measures as predictors of risk 
for periodontal diseases. Periodontology 2000, Vol. 31, 2003, 167–180. 
29) Isao Ishikawa, Akira Aoki, Aristeo A. Takasaki, Koji Mizutani, Katia M. 
Sasaki & Yuichi Izumi. Application of lasers in periodontics: true innovation 
or myth? Periodontology 2000, Vol. 50, 2009, 90–126. 
30) Walsh L. J. The current status of low level laser therapy in dentistry. Part 1. 
Soft tissue applications. Australian Dental Journal 1997; 42 :(4):247-54. 
    Bibliography 
59 
 
31)  Eberhard J, Ehlers H, Falk W, Acil Y, Albers H-K, Jepsen S. Efficacy of 
subgingival calculus removal with Er:YAG laser compared to mechanical 
debridement: an in situ study.  J Clin Periodontol 2003; 30: 511–518. 
32) Charles M. Cobb. Lasers in Periodontics: A Review of the Literature.                     
J Periodontol 2006; 77: 545-564. 
33) Krause F, Braun A, Brede O, Eberhard J, Frentzen M, Jepsen S. 
Evaluation of selective calculus removal by a fluorescence feedback-controlled 
Er:YAG laser in vitro.J Clin Periodontol 2007; 34: 66–71. 
34) Vanja vucicevic Boras, Danica Vidovic Juras, Ana Andabak Rogulj, 
Dragana Gabric Panduric, Zeljko Verzak and Vlaho Brailo. Applications 
of Low Level Laser Therapy. A Textbook of Advanced Oral and Maxillofacial 
Surgery; Chapter 12. 
35) Carlos de Paula Eduardo & Patricia Moreira de Freitas & Marcella 
Esteves-Oliveira & Ana Cecília Corrêa Aranha & Karen Müller Ramalho 
& Alyne Simões & Marina Stella Bello-Silva & Jan Tunér. Laser 
phototherapy in the treatment of periodontal disease. A review. Lasers Med Sci 
17 july 2010. 
36)  Gokce Aykol, Ulku Baser, Ilay Maden, Zafer Kazak, Utku Onan, Sevda 
Tanrikulu-Kucuk;Evin Ademoglu, Halim Issever, and Funda Yalcin. The 
Effect of Low-Level Laser Therapy as an Adjunct to Non-Surgical Periodontal 
Treatment. J Periodontol 2011;82:481-488. 
    Bibliography 
60 
 
37) Medicinski fakultet, Klinika za stomatologiju, Odeljenje za oralnu 
medicinu I parodontologiju, Nis, Srbija. Low power laser efficacy in the 
therapy of inflamed gingive in diabetics with parodontopathy. Vojnosanit 
Pregl. 2011 Aug;68(8):684-9. 
38) American Academy of Periodontology. Statement on the Efficacy of Lasers 
in the Non-Surgical Treatment of Inflammatory Periodontal Disease.                           
J Periodontol • April 2011, Volume 82 • Number 4. 
39) Radmila Obradović, Ph.D, Ljiljana Kesić, Ph.D, Dragan Mihailović, Ph.D, 
Goran Jovanović, Ph.D, Slobodan Antić, Ph.D, and Zlata Brkić, Ph.D.           
Low-Level Lasers as an Adjunct in Periodontal Therapy in Patients with 
Diabetes Mellitus. Diabetes Technol Ther. 2012 Sep; 14(9): 799–803.  
40) Catherine Giannopoulou, Isabelle Cappuyns, Jose Cancela, Norbert 
Cionca, and Andrea Mombelli. Effect of Photodynamic Therapy, Diode 
Laser, and Deep Scaling on Cytokine and Acute-Phase Protein Levels in 
Gingival Crevicular Fluid of Residual Periodontal Pockets. J Periodontol 
2012;83:1018-1027. 
41) Mellitus Radmila Obradovic Ljiljana Kesic Dragan Mihailovic Goran 
Jovanovic Slobodan Antic and Zlata Brkic. Low-Level Lasers as an Adjunct 
in Periodontal Therapy in Patients with Diabetes. Diabetes technology & 
therapeutics volume 14, number 9, 2012; 799-803. 
  
    Bibliography 
61 
 
42) Soo L, Leichter JW, Windle J, Monteith B, Williams SM, Seymour GJ. A 
comparison of Er:YAG laser and mechanical debridement for the non-surgical 
treatment of  chronic periodontitis: A randomized, prospective clinical study.          
J Clin Periodontol 2012; 39: 537–545. 
43) Walter Dukic, Ivona Bago, Andrej Aurer, and Marija Roguljic. Clinical 
Effectiveness of Diode Laser Therapy as an Adjunct to Non-Surgical 
Periodontal Treatment: A Randomized Clinical Study. J Periodontol 2013; 84: 
1111-1117. 
44) Jeffrey D. Pope, DDS, MS, Jeffrey A. Rossmann, DDS, MS, David 
G. Kerns, DMD, MS, M.Miles Beach, DMD, MS, Daisha J. Cipher, PhD.         
Use of the Carbon Dioxide Laser as an Adjunct to Scaling and Root Planing 
for Clinical New Attachment: A Case Series. Clinical Advances in 
Periodontics,vol-4,nov 2014, 209-215. 
45)  Striz Trebichavský. Calprotectin – a Pleiotropic Molecule in Acute and 
Chronic Inflammation. Physiol. Res. 53: 245-253, 2004. 
46) Andersen E, Dessaix IM, Perneger T, Mombelli A. Myeloid-related protein 
(MRP8/14) expression in gingival crevice fluid in periodontal health and 
disease and after treatment. J Periodont Res 2010; 45: 458–463. 
47) Giannopoulou C, Andersen E. Brochut P, Plagnat D, and Mombelli A. 
Enamel Matrix Derivative and Systemic Antibiotics as Adjuncts to Non-
Surgical Periodontal Treatment: Biologic Response. J Periodontol 2006; 77: 
707-713. 
    Bibliography 
62 
 
48) Dana Vieru DDS, MS, phd, Martha Cortez DDS, Lewis Clayman MD, 
DDS, and Anca Silvia Dumitriu DDS, MS, phd. Low level laser therapy in 
the treatment of periodontal disease compared study diabetics, osteoporotic 
patients, hepatic disease patients and healthy ones. Emergency dentistry, 
London 2015, Oct 3, 1741-1749. 
49) Rozana Dana vieru, Agafita Lefter and Sonia Herman. Effect of adjunct 
LASER photo biomodulation in the classical treatment of periodontal disease. 
Laser therapy; 2005, 14, 4, 161-169.  
50) Suryono, Jun-ichi-kido, Noriko H. Effect of porphyromonas gingivalis 
lipopolysaccharides, tumour necrosis factor-α and interleukin- 1β on 
calprotectin release in human monocytes. J Periodontol 2003;74:1719-1724. 
 
 
